Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

“…In some countries, efforts have been made to actively improve access and overall functioning of molecular testing for NSCLC patients through dedicated projects and policies. 81 , 82 , 83 , 84 With regard to England, it should be noted that a comprehensive overview of national predictive biomarker testing rates is currently being established by the National Disease Registration Service. In the Netherlands, molecular testing results are registered nationwide in the Dutch Pathology Registry (Palga), which enables researchers to examine these reports of patients diagnosed with NSCLC within a specified time period.…”

A local perspective on internal, external, and reflexive biomarker testing processes for lung cancer in an academic medical center

“…Additional benefits include data ownership, the potential for cost savings, and revenue generation, although exact cost estimates comparing internal and external testing have been complex to calculate, 5 and few studies have been conducted in the US health care system. [6][7][8] Another evidence-based strategy to reduce turnaround time in situations of external or internal testing is reflex testing, [9][10][11] which involves pathology placing an order for biomarker testing at the time of diagnosis without waiting for the request to come from a separate provider, typically an oncologist. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.…”

“…Additional benefits include data ownership, the potential for cost savings, and revenue generation, although exact cost estimates comparing internal and external testing have been complex to calculate, 5 and few studies have been conducted in the US health care system 6–8 . Another evidence‐based strategy to reduce turnaround time in situations of external or internal testing is reflex testing, 9–11 which involves pathology placing an order for biomarker testing at the time of diagnosis without waiting for the request to come from a separate provider, typically an oncologist.…”